Edition:
India

Lupin Ltd (LUPN.BO)

LUPN.BO on Bombay Stock Exchange

818.45INR
3:55pm IST
Change (% chg)

Rs-46.75 (-5.40%)
Prev Close
Rs865.20
Open
Rs865.05
Day's High
Rs869.95
Day's Low
Rs815.05
Volume
660,514
Avg. Vol
166,795
52-wk High
Rs1,176.00
52-wk Low
Rs723.55

Chart for

About

Lupin Limited is a pharmaceutical company. The Company is engaged in producing, developing and marketing a range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) across the world. The Company offers products in the cardiovascular, diabetology, asthma, pediatrics, central... (more)

Overall

Beta: -0.05
Market Cap(Mil.): Rs469,414.59
Shares Outstanding(Mil.): 451.84
Dividend: 7.50
Yield (%): 0.72

Financials

  LUPN.BO Industry Sector
P/E (TTM): 23.14 30.93 32.76
EPS (TTM): 44.89 -- --
ROI: -- 15.07 14.61
ROE: -- 16.60 16.34

BUZZ-Weak Q1 expected for Cadila, Lupin; improving trends for Cipla, Sun - Credit Suisse

** April-June quarter should be weak for Cadila Healthcare Ltd and Lupin Ltd with sharp declines in U.S. sales q-o-q - Credit Suisse (CS)

09 Jul 2018

Lupin expects U.S. drug pricing pressure to ease in 2019

India's second-largest drugmaker Lupin Ltd said on Wednesday it expected pressure on drug prices in the United States, which has hit its profits, to ease this year as larger rivals reduce their exposure there.

15 May 2018

UPDATE 2-India's Lupin expects U.S. drug pricing pressure to ease in 2019

* U.S. sales fall 21.1 pct; India sales up 14 pct (Adds management comments from conference call)

15 May 2018

India's Lupin posts surprise Q4 loss on one-time charge

May 15 Lupin Ltd, India's second-largest drugmaker by revenue, reported a surprise loss in its fiscal fourth quarter on Tuesday, due to a one-time charge.

15 May 2018

BRIEF-India's Lupin Posts March Quarter Consol Net Loss

* MARCH QUARTER CONSOL NET LOSS 7.84 BILLION RUPEES VERSUS PROFIT OF 3.80 BILLION RUPEES LAST YEAR

15 May 2018

BRIEF-Lupin Launches Corcal Bone And Beauty Supplement

* LAUNCHES CORCAL BONE AND BEAUTY SUPPLEMENT Source text: http://bit.ly/2I8514t Further company coverage:

10 May 2018

BRIEF-Lupin Submits New Drug Application For Etanercept Biosimilar In Japan

* SAYS SUBMITS NEW DRUG APPLICATION FOR ETANERCEPT BIOSIMILAR IN JAPAN

08 May 2018

BRIEF-India's Lupin Gets FDA Approval For Generic Temovate Ointment, 0.05 Percent

* GETS FDA APPROVAL FOR GENERIC TEMOVATE OINTMENT, 0.05 PERCENT

07 May 2018

BRIEF-India's Lupin Gets FDA Nod For Generic Xenazine Tablets, 12.5 Mg And 25 Mg

* SAYS CO RECEIVES FDA APPROVAL FOR GENERIC XENAZINE TABLETS, 12.5 MG AND 25 MG Source text - http://bit.ly/2qUd2T4 Further company coverage:

23 Apr 2018

BRIEF-India's Lupin Gets Tentative U.S. FDA Nod For Generic Androgel, 1.62 Pct

* SAYS CO RECEIVES TENTATIVE FDA APPROVAL FOR GENERIC ANDROGEL, 1.62 PERCENT Source text - https://bit.ly/2HEhHk8 Further company coverage:

17 Apr 2018

Earnings vs. Estimates